Hims & Hers Health, Inc. $HIMS Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 4.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,518,015 shares of the company’s stock after buying an additional 844,991 shares during the period. Vanguard Group Inc. owned about 0.09% of Hims & Hers Health worth $1,107,062,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in shares of Hims & Hers Health by 0.8% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock valued at $1,452,000 after acquiring an additional 200 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Hims & Hers Health by 6.1% during the third quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock worth $232,000 after purchasing an additional 236 shares in the last quarter. Concurrent Investment Advisors LLC raised its stake in Hims & Hers Health by 1.8% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock valued at $793,000 after purchasing an additional 252 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in Hims & Hers Health by 44.7% in the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after purchasing an additional 283 shares in the last quarter. Finally, Bessemer Group Inc. boosted its stake in Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $15.62 on Friday. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The company has a market capitalization of $3.56 billion, a PE ratio of 28.93, a price-to-earnings-growth ratio of 2.92 and a beta of 2.43. The firm’s 50-day moving average is $28.63 and its two-hundred day moving average is $40.35. Hims & Hers Health, Inc. has a 12 month low of $15.29 and a 12 month high of $70.43.

Hims & Hers Health declared that its board has approved a share buyback plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 3% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. BTIG Research dropped their target price on shares of Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating for the company in a report on Monday, February 2nd. TD Cowen lowered their price target on shares of Hims & Hers Health from $30.00 to $20.00 and set a “hold” rating on the stock in a research report on Monday, February 9th. Deutsche Bank Aktiengesellschaft set a $31.00 price objective on shares of Hims & Hers Health and gave the company a “hold” rating in a research note on Tuesday, February 10th. Evercore assumed coverage on shares of Hims & Hers Health in a research note on Monday, January 12th. They issued an “in-line” rating and a $33.00 target price on the stock. Finally, Barclays began coverage on Hims & Hers Health in a report on Monday, December 8th. They set an “overweight” rating and a $48.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $39.32.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Acquisition expands international footprint and revenue run‑rate — Hims & Hers agreed to buy Australian digital‑health provider Eucalyptus in a deal worth up to $1.15 billion, a move management says will accelerate global growth and add a high‑growth revenue stream. Hims & Hers Health to acquire Australia’s Eucalyptus for up to $1.15 billion
• Positive Sentiment: Deal expected to materially increase top line and international scale — Coverage notes Eucalyptus brings ~ $450M of annual revenue growing at triple‑digit rates and should accelerate HIMS’ personalized care footprint outside the U.S. Hims & Hers HUGE Acquisition News!
• Positive Sentiment: Product/technology expansion — Hims is ramping AI‑driven preventive care (menopause, low testosterone, multi‑cancer testing and deeper personalization), which supports a higher‑value platform positioning longer term. Hims & Hers Accelerates AI Preventive Care and Platform Strategy
• Neutral Sentiment: Analysts flag mixed near‑term earnings implications — Some previews say platform strength and new specialties could help Q4 results, but recognize higher costs tied to deals and expansion may cloud near‑term profitability. Can Platform Strength Support Hims & Hers Stock Before Q4 Earnings?
• Negative Sentiment: Regulatory and legal scrutiny around GLP‑1/weight‑loss products — Coverage reports the company’s earlier GLP‑1/compounder strategy drew backlash from drugmakers and regulators, raising compliance, litigation and reputational risks that could hurt sales and margins. Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders
• Negative Sentiment: Reputational headlines and legal risk over “copycat” weight‑loss drugs — Media coverage and analysis highlight mounting criticism that could pressure demand or invite enforcement actions. Hims & Hers under fire over copycat weight loss drugs
• Neutral Sentiment: Deal financing and integration risk — Commentators note HIMS will use significant cash (and potentially other consideration) for the deal, raising questions about near‑term balance sheet flexibility and execution risk on integrating Eucalyptus. Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills?

Insider Activity

In related news, COO Michael Chi sold 13,750 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $504,762.50. Following the transaction, the chief operating officer directly owned 305,161 shares in the company, valued at approximately $11,202,460.31. This represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Irene Becklund sold 8,411 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $308,767.81. Following the completion of the transaction, the insider owned 2,126 shares of the company’s stock, valued at $78,045.46. The trade was a 79.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 82,963 shares of company stock worth $2,944,621. 13.71% of the stock is owned by company insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.